Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

NCT07374445 · Completed

Last updated 2026-05-28

This clinical trial is testing whether giving the medication liraglutide at different times after weight-loss surgery helps patients with obesity lose more weight.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 100 people

Who can join Ages 18–65 · all sexes

Timeline Started 2023-09 · est. completion 2025-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07374445 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to compare the weight loss and metabolic benefit in patients remaining obesity at 6 months after metabolic surgery. The main questions it aims to answer are: \[primary hypothesis 1\] Whether liraglutide benefits weight loss when it is initiated early after metabolic surgery. \[primary hypothesis 2\] Whether weight loss and metabolic benefits are greater when linaglutide is initiated in patients who are obese at 6 months after metabolic surgery

Treatments tested

Liraglutide injection Drug

Patients received a 24-week regimen of once-daily liraglutide, initiated at 0.6 mg/day and titrated weekly by 0.6 mg to a maximum tolerated dose of up to 3.0 mg/day.
Diet and exercise guidelines Behavioral

Participants followed a science-based diet and exercise program intervention

Main thing measured	Change in %TWL from baseline to endpoint across patient groups
Sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions studied	Obesity, Weight Loss, Bariatric Surgery
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07374445 ↗